Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 26 Show results per page	View Search Criteria \| Help With Results


1.		The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Other				2612-2277 NCT00122720


2.		A Study of the Management of Blood Loss in Patients Undergoing Surgical Removal of Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				CR003460 NCT00264095


3.		Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care				Closed				Over 18				Other				2005-005658-37 LM: 2612-3148, Ethical: 20060074, Data Protection: 2005-41-6015, NCT00381836


4.		Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Completed				16 to 69				Other				TJE0301 NCT00557817

Last Modified: 9/10/2003 First Published: 10/1/2002


5.		Phase III Randomized Study of Darbepoetin alfa Versus Epoetin alfa for Anemia in Patients With Non-Myeloid Malignancies Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0201098 NCI-G02-2112, AMGEN-200101101, NCT00046982

Last Modified: 5/23/2007 First Published: 9/24/2003


6.		Phase III Randomized Study of Darbepoetin alfa Versus Epoetin alfa for Anemia in Patients With Non-Myeloid Malignancies Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0306021 AMGEN-20030125, NCT00070382

Last Modified: 5/23/2007 First Published: 11/22/2004


7.		Phase III Randomized Study of Darbepoetin alfa For Treatment of Anemia in Patients With Non-Myeloid Cancer Who Are Not Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0403046-01 AMGEN-20010103, NCT00098696


8.		A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				20010145 NCT00119613


9.		AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				Pharmaceutical / Industry				20040156 NCT00135317


10.		Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				18 and over				Other				04/Q1907/94 NCT00234143

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute